Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
07:00am, Thursday, 20'th Nov 2025
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
07:00am, Thursday, 20'th Nov 2025
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash b
Moderna to complete US mRNA manufacturing network with $140 million investment
08:44am, Wednesday, 19'th Nov 2025
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
07:00am, Wednesday, 19'th Nov 2025
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturi
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
07:00am, Tuesday, 18'th Nov 2025
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annu
What Is Going On With Moderna Stock?
09:25am, Thursday, 13'th Nov 2025
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over th
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA
03:48am, Wednesday, 12'th Nov 2025
Acadian Asset Management LLC lifted its position in Moderna, Inc. (NASDAQ: MRNA) by 284.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
12:59pm, Monday, 10'th Nov 2025
Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM,
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
11:30pm, Thursday, 06'th Nov 2025
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
03:26pm, Thursday, 06'th Nov 2025
Moderna, Inc. ( MRNA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - C
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue Challenges
02:11pm, Thursday, 06'th Nov 2025
Revenue: $1 billion for Q3 2025.Net Loss: $200 million for Q3 2025.Cash and Investments: $6.6 billion at the end of Q3 2025.Cost Reduction: 34% reduction in co
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
01:01pm, Thursday, 06'th Nov 2025
Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.15. In the year-ago period, the company had reported earnin
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
12:29pm, Thursday, 06'th Nov 2025
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
09:15am, Thursday, 06'th Nov 2025
Moderna (MRNA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $0.03 per share a year ago.
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estimate, Revenue Surpasses Expectations at $1.0 Billion
07:32am, Thursday, 06'th Nov 2025
Revenue: Reported $1.0 billion for Q3 2025, surpassing the estimated $886.54 million.Net Loss: Recorded a GAAP net loss of $200 million, a significant shift fr
